NEW YORK, May 07, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets
released its latest key findings for all current investors, traders, and shareholders of CASI Pharmaceuticals, Inc. (NASDAQ:CASI),
Energy Transfer Partners, L.P. (NYSE:ETP), Cypress Semiconductor Corporation (NASDAQ:CY), Xcel Energy Inc. (NASDAQ:XEL), Ironwood
Pharmaceuticals, Inc. (NASDAQ:IRWD), and KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), including updated fundamental summaries,
consolidated fiscal reporting, and fully-qualified certified analyst research.
Complimentary Access: Research Reports
Full copies of recently published reports are available to readers at the links below.
CASI DOWNLOAD: http://Fundamental-Markets.com/register/?so=CASI
ETP DOWNLOAD: http://Fundamental-Markets.com/register/?so=ETP
CY DOWNLOAD: http://Fundamental-Markets.com/register/?so=CY
XEL DOWNLOAD: http://Fundamental-Markets.com/register/?so=XEL
IRWD DOWNLOAD: http://Fundamental-Markets.com/register/?so=IRWD
KALV DOWNLOAD: http://Fundamental-Markets.com/register/?so=KALV
(You may have to copy and paste the link into your browser and hit the [ENTER] key)
The new research reports from Fundamental Markets, available for free download at the links above, examine CASI Pharmaceuticals,
Inc. (NASDAQ:CASI), Energy Transfer Partners, L.P. (NYSE:ETP), Cypress Semiconductor Corporation (NASDAQ:CY), Xcel Energy Inc.
(NASDAQ:XEL), Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), and KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) on a fundamental level
and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy,
management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to
today's readers below.
-----------------------------------------
Important Notice: the following excerpts are not designed to be standalone summaries and as such,
important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you
are reading all relevant material information. All information in this release was accessed May 4th, 2018. Percentage calculations
are performed after rounding. All amounts in millions (MM), except per share amounts.
-----------------------------------------
CASI PHARMACEUTICALS, INC. (CASI) REPORT OVERVIEW
CASI Pharmaceuticals' Recent Financial Performance
For the twelve months ended December 31st, 2017 vs December 31st, 2016, CASI Pharmaceuticals reported revenue of $0.00MM vs
$0.00MM and basic earnings per share -$0.18 vs -$0.17. CASI Pharmaceuticals is expected to report earnings on May 21st, 2018. The
report will be for the fiscal period ending March 31st, 2018. The reported EPS for the same quarter last year was -$0.03. The
estimated EPS forecast for the next fiscal year is -$0.16 and is expected to report on April 4th, 2019.
To read the full CASI Pharmaceuticals, Inc. (CASI) report, download it here: http://Fundamental-Markets.com/register/?so=CASI
-----------------------------------------
ENERGY TRANSFER PARTNERS, L.P. (ETP) REPORT OVERVIEW
Energy Transfer Partners' Recent Financial Performance
For the three months ended December 31st, 2017 vs December 31st, 2016, Energy Transfer Partners reported revenue of $11,803.00MM
vs $9,230.00MM (up 27.88%) and basic earnings per share -$0.77 vs -$1.30. For the twelve months ended December 31st, 2017 vs
December 31st, 2016, Energy Transfer Partners reported revenue of $29,054.00MM vs $21,827.00MM (up 33.11%) and basic earnings per
share $0.94 vs -$1.38.
To read the full Energy Transfer Partners, L.P. (ETP) report, download it here: http://Fundamental-Markets.com/register/?so=ETP
-----------------------------------------
CYPRESS SEMICONDUCTOR CORPORATION (CY) REPORT OVERVIEW
Cypress Semiconductor's Recent Financial Performance
For the three months ended March 31st, 2018 vs March 31st, 2017, Cypress Semiconductor reported revenue of $582.24MM vs
$531.87MM (up 9.47%) and basic earnings per share $0.03 vs -$0.13. For the twelve months ended December 31st, 2017 vs December
31st, 2016, Cypress Semiconductor reported revenue of $2,327.77MM vs $1,923.11MM (up 21.04%) and basic earnings per share -$0.24 vs
-$2.14. Cypress Semiconductor is expected to report earnings on July 26th, 2018. The report will be for the fiscal period ending
June 30th, 2018. The reported EPS for the same quarter last year was $0.13. The estimated EPS forecast for the next fiscal year is
$1.16 and is expected to report on February 7th, 2019.
To read the full Cypress Semiconductor Corporation (CY) report, download it here: http://Fundamental-Markets.com/register/?so=CY
-----------------------------------------
XCEL ENERGY INC. (XEL) REPORT OVERVIEW
Xcel Energy's Recent Financial Performance
For the three months ended March 31st, 2018 vs March 31st, 2017, Xcel Energy reported revenue of $2,951.00MM vs $2,946.00MM (up
0.17%) and basic earnings per share $0.57 vs $0.47 (up 21.28%). For the twelve months ended December 31st, 2017 vs December 31st,
2016, Xcel Energy reported revenue of $11,404.00MM vs $11,107.00MM (up 2.67%) and basic earnings per share $2.26 vs $2.21 (up
2.26%). Xcel Energy is expected to report earnings on July 26th, 2018. The report will be for the fiscal period ending June 30th,
2018. The reported EPS for the same quarter last year was $0.45. The estimated EPS forecast for the next fiscal year is $2.59 and
is expected to report on February 6th, 2019.
To read the full Xcel Energy Inc. (XEL) report, download it here: http://Fundamental-Markets.com/register/?so=XEL
-----------------------------------------
IRONWOOD PHARMACEUTICALS, INC. (IRWD) REPORT OVERVIEW
Ironwood Pharmaceuticals' Recent Financial Performance
For the three months ended December 31st, 2017 vs December 31st, 2016, Ironwood Pharmaceuticals reported revenue of $94.21MM vs
$87.46MM (up 7.72%) and basic earnings per share $0.10 vs -$0.09. For the twelve months ended December 31st, 2017 vs December 31st,
2016, Ironwood Pharmaceuticals reported revenue of $298.28MM vs $273.96MM (up 8.88%) and basic earnings per share -$0.78 vs -$0.56.
Ironwood Pharmaceuticals is expected to report earnings on August 2nd, 2018. The report will be for the fiscal period ending June
30th, 2018. The reported EPS for the same quarter last year was -$0.28. The estimated EPS forecast for the next fiscal year is
$0.05 and is expected to report on February 21st, 2019.
To read the full Ironwood Pharmaceuticals, Inc. (IRWD) report, download it here: http://Fundamental-Markets.com/register/?so=IRWD
-----------------------------------------
KALVISTA PHARMACEUTICALS, INC. (KALV) REPORT OVERVIEW
KalVista Pharmaceuticals' Recent Financial Performance
For the three months ended January 31st, 2018 vs January 31st, 2017, KalVista Pharmaceuticals reported revenue of $2.33MM vs
$0.25MM (up 839.92%) and basic earnings per share -$0.49 vs -$1.03. For the twelve months ended April 30th, 2017 vs April 30th,
2016, KalVista Pharmaceuticals reported revenue of $1.50MM vs $2.13MM (down 29.49%) and basic earnings per share -$4.47 vs
-$26.17.
To read the full KalVista Pharmaceuticals, Inc. (KALV) report, download it here: http://Fundamental-Markets.com/register/?so=KALV
-----------------------------------------
ABOUT FUNDAMENTAL MARKETS
Fundamental Markets serves thousands of members and have provided research through some of the world's leading brokerages for
over a decade – and continue to be one of the best information sources for investors and investment professionals worldwide.
Fundamental Markets' roster boasts decades of financial experience and includes top financial writers, FINRA® BrokerCheck®
certified professionals with current and valid CRD® number designations, as well as Chartered Financial Analyst® (CFA®) designation
holders, to ensure up to date factual information for active readers on the topics they care about.
REGISTERED MEMBER STATUS
Fundamental Markets' oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered
Members") working within Equity Research, Media, and Compliance departments. Fundamental Markets' roster includes qualified CFA®
charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed
status of several Registered Members at Fundamental Markets have been independently verified by an outside audit firm, including
policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release
should be directed to Fundamental Markets' Compliance department by Phone, at +1 667-401-0010, or by E-mail at
compliance@Fundamental-Markets.com.
LEGAL NOTICES
Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Fundamental Markets,
Fundamental Markets members, and/or Fundamental Markets affiliates are not responsible for any gains or losses that result from the
opinions expressed. Fundamental Markets makes no representations as to the completeness, accuracy, or timeliness of the material
provided and all materials are subject to change without notice. Fundamental Markets has not been compensated for the publication
of this press release by any of the above mentioned companies. Fundamental Markets is not a financial advisory firm, investment
adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer,
disclosure, and terms of service please visit our website.
Media Contact:
Andrew Duffie, Media Department
Office: +1 667-401-0010
E-mail: media@Fundamental-Markets.com
© 2018 Fundamental Markets. All Rights Reserved. For republishing permissions, please contact a partner network
manager at partnership@Fundamental-Markets.com.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority,
Inc.
